MURA Maiken Keson-Brookes sells $8K worth of shares
Dec 27, 2024, 5:33 AM
22.67%
What does MURA do
Mural Oncology Plc is a clinical-stage company developing cytokine-based immunotherapies for cancer using its protein engineering platform. Its portfolio includes Nemvaleukin alfa and a tumor-targeted split IL-12 program.
Maiken Keson-Brookes sold 2,555 shares of MURA on 23 December at $3.27 per share, worth a total of $8K. They now own 41,295 MURA shares, or a 6% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
